288 related articles for article (PubMed ID: 25079790)
41. In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii.
Martins-Duarte ES; Portes JA; da Silva RB; Pires HS; Garden SJ; de Souza W
Bioorg Med Chem; 2021 Nov; 50():116467. PubMed ID: 34666274
[TBL] [Abstract][Full Text] [Related]
42. Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
Vidadala RS; Rivas KL; Ojo KK; Hulverson MA; Zambriski JA; Bruzual I; Schultz TL; Huang W; Zhang Z; Scheele S; DeRocher AE; Choi R; Barrett LK; Siddaramaiah LK; Hol WG; Fan E; Merritt EA; Parsons M; Freiberg G; Marsh K; Kempf DJ; Carruthers VB; Isoherranen N; Doggett JS; Van Voorhis WC; Maly DJ
J Med Chem; 2016 Jul; 59(13):6531-46. PubMed ID: 27309760
[TBL] [Abstract][Full Text] [Related]
43. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
44. Screening of compound libraries for inhibitors of Toxoplasma growth and invasion.
Han Y; Adeyemi OS; Kabir MHB; Kato K
Parasitol Res; 2020 May; 119(5):1675-1681. PubMed ID: 32236711
[TBL] [Abstract][Full Text] [Related]
45. Dichloroacetate and Pyruvate Metabolism: Pyruvate Dehydrogenase Kinases as Targets Worth Investigating for Effective Therapy of Toxoplasmosis.
Ferrarini MG; Nisimura LM; Girard RMBM; Alencar MB; Fragoso MSI; Araújo-Silva CA; Veiga AA; Abud APR; Nardelli SC; Vommaro RC; Silber AM; France-Sagot M; Ávila AR
mSphere; 2021 Jan; 6(1):. PubMed ID: 33408226
[TBL] [Abstract][Full Text] [Related]
46. IL-10 is not required to prevent immune hyperactivity during memory responses to Toxoplasma gondii.
Wille U; Nishi M; Lieberman L; Wilson EH; Roos DS; Hunter CA
Parasite Immunol; 2004 May; 26(5):229-36. PubMed ID: 15491472
[TBL] [Abstract][Full Text] [Related]
47. Essential oil of oregano (Origanum vulgare L.) reduces infection and proliferation of Toxoplasma gondii in BeWo cells with induction of autophagy and death of tachyzoites through a mechanism similar to necrosis.
Nunes AP; Dos Santos YM; da Silva Sanfelice RA; Concato-Lopes VM; Silva TF; Tomiotto-Pellissier F; Lazarin-Bidoia D; Machado RRB; de Barros LD; Garcia JL; Conchon-Costa I; Pavanelli WR; Kobayashi RKT; de Freitas Barbosa B; Ferro EAV; Costa IN
Parasitol Res; 2024 May; 123(5):217. PubMed ID: 38772951
[TBL] [Abstract][Full Text] [Related]
48. The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection.
Araujo FG; Khan AA; Slifer TL; Bryskier A; Remington JS
Antimicrob Agents Chemother; 1997 Oct; 41(10):2137-40. PubMed ID: 9333038
[TBL] [Abstract][Full Text] [Related]
49. Assessment of the Activity of Decoquinate and Its Quinoline-
Ramseier J; Imhof D; Anghel N; Hänggeli K; Beteck RM; Balmer V; Ortega-Mora LM; Sanchez-Sanchez R; Ferre I; Haynes RK; Hemphill A
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770802
[TBL] [Abstract][Full Text] [Related]
50. Gefitinib inhibits the growth of Toxoplasma gondii in HeLa cells.
Yang Z; Ahn HJ; Nam HW
Korean J Parasitol; 2014 Aug; 52(4):439-41. PubMed ID: 25246725
[TBL] [Abstract][Full Text] [Related]
51.
Adeyemi OS; Atolani O; Awakan OJ; Olaolu TD; Nwonuma CO; Alejolowo O; Otohinoyi DA; Rotimi D; Owolabi A; Batiha GE
Yale J Biol Med; 2019 Sep; 92(3):369-383. PubMed ID: 31543702
[TBL] [Abstract][Full Text] [Related]
52. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
Martins-Duarte ÉS; de Souza W; Vommaro RC
Exp Parasitol; 2013 Mar; 133(3):294-9. PubMed ID: 23270807
[TBL] [Abstract][Full Text] [Related]
53. Effect of Nigella sativa oil on experimental toxoplasmosis.
Mady RF; El-Hadidy W; Elachy S
Parasitol Res; 2016 Jan; 115(1):379-90. PubMed ID: 26446086
[TBL] [Abstract][Full Text] [Related]
54. One-pot, multicomponent synthesis of 2,3-disubstituted quinazolin-ones with potent and selective activity against Toxoplasma gondii.
Brown CE; Kong T; Bordón C; Yolken R; Jones-Brando L; McNulty J
Bioorg Med Chem Lett; 2018 May; 28(9):1642-1646. PubMed ID: 29598911
[TBL] [Abstract][Full Text] [Related]
55. In vitro evaluation of new 4-thiazolidinones on invasion and growth of Toxoplasma gondii.
Molina DA; Ramos GA; Zamora-Vélez A; Gallego-López GM; Rocha-Roa C; Gómez-Marin JE; Cortes E
Int J Parasitol Drugs Drug Resist; 2021 Aug; 16():129-139. PubMed ID: 34102589
[TBL] [Abstract][Full Text] [Related]
56. Anti-
Teimouri A; Azami SJ; Keshavarz H; Esmaeili F; Alimi R; Mavi SA; Shojaee S
Int J Nanomedicine; 2018; 13():1341-1351. PubMed ID: 29563791
[TBL] [Abstract][Full Text] [Related]
57. Cathepsin Cs are key for the intracellular survival of the protozoan parasite, Toxoplasma gondii.
Que X; Engel JC; Ferguson D; Wunderlich A; Tomavo S; Reed SL
J Biol Chem; 2007 Feb; 282(7):4994-5003. PubMed ID: 17164247
[TBL] [Abstract][Full Text] [Related]
58. Could miltefosine be used as a therapy for toxoplasmosis?
Eissa MM; Barakat AM; Amer EI; Younis LK
Exp Parasitol; 2015 Oct; 157():12-22. PubMed ID: 26112396
[TBL] [Abstract][Full Text] [Related]
59. Antiparasitic effects of oxymatrine and matrine against Toxoplasma gondii in vitro and in vivo.
Zhang X; Jin L; Cui Z; Zhang C; Wu X; Park H; Quan H; Jin C
Exp Parasitol; 2016 Jun; 165():95-102. PubMed ID: 26993085
[TBL] [Abstract][Full Text] [Related]
60. Phytoecdysteroids as modulators of the Toxoplasma gondii growth rate in human and mouse cells.
Dzitko K; Grzybowski MM; Pawełczyk J; Dziadek B; Gatkowska J; Stączek P; Długońska H
Parasit Vectors; 2015 Aug; 8():422. PubMed ID: 26272689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
